PI3K / Akt / mTOR



Items 1 to 50 of 215 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction
Catalog No. Product Name Application Product Information
A12720

TIC10 isomer

AKT inhibitor‎
TIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics.
A16286

ARQ-092 (Miransertib)

AKT inhibitor
ARQ 092 is an oral activie, potent and selective AKT inhibitor with IC50 values: 5.0 nM (AKT1); 4.5 nM (AKT2); 16 nM (AKT3).
A16285

Akt1 and Akt2-IN-1

AKT 1/2 inhibitor
Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC50 = 3.5 nM) and Akt2 (IC50 = 42 nM), with potent and balanced activity.
A15903

TIC10

Akt Inhibitor‎
TIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.
A12081 SALE

SC 66

Akt inhibitor
SC 66 is an allosteric inhibitor of Akt that facilitates both ubiquitination and deactivation of Akt. It exhibits anticancer activity in vitro and in vivo.
A15809

GSK2141795 (Uprosertib, GSK795)

Akt inhibitor
Akt inhibitor GSK2141795 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis.
A15541 SALE

SC79

Akt phosphorylation activator
SC79 is an AKT activator. SC79 binds to the plecktrin homology (PH) domain of Akt that mimics the binding of PtdIns(3,4,5)P3 to induce a conformational change in Akt that enhances phosphorylation and activation.
A13030 SALE

Afuresertib HCl

AKT inhibitor‎
Afuresertib, also known as GSK2110183, is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. It binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.
A13554

SR-13668

AKT inhibitor‎
SR-13668 is an Akt inhibitor, is also an orally bioavailable indole-3-carbinol (I3C) analogue inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic and antiangiogenic activities.
A13590

10-DEBC HCl

AKT/PKB inhibitor‎
10-DEBC HCl is a selective inhibitor of Akt/PKB. It inhibits IGF-1-stimulated phosphorylation and activation of Akt (complete inhibition at 2.5 μM), suppressing downstream activation of mTOR, p70 S6 kinase and S6 ribosomal protein.
A11246 SALE

GDC-0068 (Ipatasertib, RG-7440)

Akt Inhibitor
GDC-0068 is a selective, ATP-competitive, pan-Akt inhibitor that targets Akt1, 2, and 3 with IC50 values of 5, 18, and 8 nM, respectively in cell-free assays
A12877

KP372-1

Akt Inhibitor
KP372-1 is a synthetic small molecule AKT inhibitor.
A13460 SALE

Deguelin

-
Deguelin is a natural product that displays profound antiproliferative activity.
A13210 SALE

Triciribine

AKT Inhibitor
Triciribine, also known as API-2, suppresses the phosphorylation level and kinase activity of Akt.
A12435

Akt-l-1

AKT1 inhibitor
Akt-I-1 is a specific inhibitor of Akt1 (IC(50) 4.6 µM) and does not inhibit AKT2, or AKT3
A12464

AT13148

multi-AGC kinase inhibitor
AT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors.
A14138

Miltefosine

PI3K/Akt inhibitor
Miltefosine inhibits PI3K/Akt activity with ED50 of 17.2 μM and 8.1 μM in carcinoma cell lines A431 and HeLa
A15006

AT7867 2HCl

Akt inhibitor
AT7867 dihydrochloride is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively, little activity outside the AGC kinase family.
A16233

Tomatidine

ERK/Akt/NF-kB inhibitor
Tomatidine inhibits the phosphorylation of ERK, Akt, and the nuclear content of NF-kB. possess anti-inflammatory properties.
A16392

Afuresertib

Akt inhibitor
Afuresertib is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
A11759 SALE

AZD5363

AKT inhibitor
AZD5363 is a potent inhibitor of AKT with pharmacodynamic activity in vivo, has potential to treat a range of solid and hematologic tumors as monotherapy or a combinatorial agent.
A11287 SALE

A-443654

Akt inhibitor
A-443654, a specific Akt inhibitor with Ki value of 160 pM, interferes with mitotic progression and bipolar spindle formation.
A11286 SALE

AKT inhibitor VIII (AKTI-1/2)

AKT inhibitor
AKT inhibitor VIII is a cell-permeable and reversible quinoxaline compound that potently and selectively inhibits Akt1/Akt2 activity (IC50 = 58 nM, 210 nM, and 2.12 ?M for Akt1, Akt2, and Akt3, respectively, in in vitro kinase assays).
A10003 SALE

MK-2206 2HCl

AKT Inhibitor
MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively.
A10709 SALE

Perifosine (NSC-639966)

Akt inhibitor
Perifosine (also KRX-0401) acts as an Akt inhibitor and a PI3K inhibitor.
A11024 SALE

PF-04691502

PI3K/mTOR Inhibitor
PF-04691502 is a PI3K/mTOR kinase inhibitor, is also an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway.
A11030 SALE

GSK690693

AKT inhibitor
GSK690693 is a novel ATP-competitive, low-nanomolar pan-Akt kinase inhibitor (IC50 values are 2, 13 and 9 nM of Akt1, 2 and 3 respectively).
A10094

AT7867

AKT inhibitor
AT7867 is a novel and potent inhibitor of both AKT and the downstream kinase p70 S6 kinase (p70S6K) and also of protein kinase A.
A11031 SALE

CCT128930

AKT Inhibitor
CCT128930 is an ATP-competitive AKT inhibitor that is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA, achieved by targeting a single amino acid difference.
A11032 SALE

PHT-427

AKT Inhibitor
PHT-427 is a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.
A11033 SALE

Triciribine phosphate (NSC-280594)

AKT Inhibitor
Triciribine phosphate inhibits the phosphorylation, activation, and signalling of Akt-1, -2, and -3, which may result in the inhibition of Akt-expressing tumor cell proliferation.
A11034 SALE

A-674563

Akt inhibitor
A-674563 is a B/Akt inhibitor with an IC50 of 14 nM and also shows inhibitory activity against PKA and CDK2 with IC50 of 16 and 46 nM, respectively.
A10453 SALE

Honokiol

Antiangiogenic and Antitumor Agent
Honokiol is a lignan present in the cones, bark, and leaves of Magnolia grandiflora that has shown pro-apoptotic effects in melanoma, sarcoma, myeloma, leukemia, bladder, lung, prostate, oral squamous cell carcinoma and colon cancer cell lines.
A16270

PI4KIIIbeta-IN-9

PI4KIIIβ inhibitor
PI4KIIIbeta-IN-9 is a potent PI4KIIIbeta inhibitor (IC50 of 7 nM) and is >140-fold selective over PI3Kgamma and >20-fold selective over PI3Kδ, and shows no inhibition of vps34 at concentrations up to 20 uM.
A16269

PI4KIIIbeta-IN-10

PI4KIIIβ inhibitor
PI4KIIIbeta-IN-10 is the most potent PI4KIIIbeta inhibitor currently reported, with very minor off-target inhibition of PI4KIIIbeta related lipid kinases (IC50 = 3.6 nM).
A16266

ON 146040

dual PI3K and BCR-ABL inhibitor
ON 146040 is the first dual PI3K and BCR-ABL inhibitor that targets the STAT3 and STAT5 pathways; inhibits PI3K α/δ isoforms with IC50 of 14/20 nM.
A16126

LY3023414

PI3K/mTOR Dual Inhibitor
LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK, extracted from patent WO/2012097039A1, compound example 1, has an IC50 of 64.9 nM, 42.1 nM, 10.6 nM, 19.1 nM for Akt1(pT308), Akt1 (pS473), P70S6(pT389), S6RP(pS240/242).
A13992

GNE-317

PI3K inhibitor
GNE-317 is a potent PI3K inhibitor that can cross the Blood brain barrier; shows potent suppression of the PI3K pathway in the brain of mice with intact BBB.
A16271

ETP-46321

PI3K α/δ inhibitor
ETP-46321 is a potent and orally bioavailable PI3K α/δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after oral dosing.
A16272

GDC-0084

PI3K inhibitor
GDC-0084 is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity.
A16273

NVP-QAV-572

PI3K inhibitor
NVP-QAV-572 is a potent PI3K kianse inhibitor with IC50 of 10 nM.
A16274

PI3K-alpha inhibitor 1

PI3Kα inhibitor
PI3Kα inhibitor 1 is a PI3Kα inhibitor extracted from patent US/20120088764A1, compound 243, has an IC50 < 0.1 uM, PI3Kα inhibitor 1 also inhibits HDAC (0.1 uM ≤ IC50 ≤ 1 uM) .
A16275

PI3K-gamma inhibitor 1

PI3Kγ inhibitor
PI3Kγ inhibitor 1 is a potent PI3Kγ inhibitor.
A16276

SAR245409 (XL765, Voxtalisib)

PI3K/mTOR dual inhibitor
SAR245409 is a PI3K/mTOR dual kinase inhibitor XL765 is an orally bioavailable small molecule targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K/mTOR signaling pathway, with potential antineoplastic activity.
A16277

TGR-1202

PI3Kδ inhibitor
TGR-1202 is an orally available, next generation PI3Kδ inhibitor, inhibits PI3Kδ activity in enzyme and cell based assays with IC50 and EC50 values of 22.2 and 24.3 nM respectively.
A16278

TGR-1202 hydrochloride

PI3Kδ inhibitor
TGR-1202 hydrochloride is an orally available, next generation PI3Kδ inhibitor, inhibits PI3Kδ activity in enzyme and cell based assays with IC50 and EC50 values of 22.2 and 24.3 nM respectively.
A15992

PQR309

PI3K inhibitor
PQR309 is an orally bioavailable pan inhibitor of phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), with potential antineoplastic activity.
A12889

PF-4989216

PI3K inhibitor
PF-4989216 is a potent and selective PI3K inhibitor with IC50 of 2 nM, 142 nM, 65 nM, 1 nM, and 110 nM for p110??, p110??, p110??, p110??, and VPS34, respectively.
A12480 SALE

VS-5584

PI3K/mTOR inhibitor
VS-5584 is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.
A13021 SALE

HS-173

PI3K Inhibitor
HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis.

Items 1 to 50 of 215 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction